Market Place
Sourcing Support
ImCheck Presents AML Results from EVICTION Trial at ASH 2024
26 Nov 2024 //
GLOBENEWSWIRE
ImCheck Presents Updated Data from EVICTION Trial at SITC 2024
05 Nov 2024 //
GLOBENEWSWIRE
ImCheck Receives FDA Fast Track For ICT01 In AML
18 Sep 2024 //
GLOBENEWSWIRE
ImCheck Appoints Stephan Braun as Chief Medical Officer
09 Jul 2024 //
GLOBENEWSWIRE
ImCheck to Present Promising ICT01 Data from the EVICTION Study at ASCO 2024
30 May 2024 //
GLOBENEWSWIRE
ImCheck Presented Positive Data from Phase I/IIa EVICTION-2 Trial of ICT01
03 Nov 2023 //
GLOBENEWSWIRE
ImCheck To Present EVICTION-2 Data on ICT01 Combination With Low Dose IL-2
30 Oct 2023 //
GLOBENEWSWIRE
ImCheck to Present New Positive Data on ICT01 Monotherapy
18 Oct 2023 //
GLOBENEWSWIRE
ImCheck to Present Positive Data on ICT01 Monotherapy in Hematological Cancers
15 Oct 2023 //
GLOBENEWSWIRE
ImCheck Achieves the Primary Objectives of PhI of the EVICTION-2 Trial of ICT01
18 Apr 2023 //
GLOBENEWSWIRE
ImCheck Appoints Thomas Civik as Independent Chairman of the Board
23 Mar 2023 //
GLOBENEWSWIRE
ImCheck To Present Data From EVICTION-2 Study of ICT01 in Combination With IL-2
14 Mar 2023 //
GLOBENEWSWIRE
ImCheck Presents Initial Patient Data from the EVICTION-2 Trial at SITC
11 Nov 2022 //
GLOBENEWSWIRE
Presents +ve Safety and Efficacy Data from the Completed Ph1 Dose Escalation
10 Sep 2022 //
GLOBENEWSWIRE
ImCheck Closes Upsized EUR 96M Financing to Advance Clinical Program
13 Jun 2022 //
GLOBENEWSWIRE
ImCheck Provides Updated ICT01 + Pembrolizumab Data from PI/IIa EVICTION Trial
08 Apr 2022 //
GLOBENEWSWIRE
ImCheck to Present at 40th Annual J.P. Morgan Healthcare Conference
06 Jan 2022 //
GLOBENEWSWIRE
ImCheck Provides Patient Response Data from Phase I/IIa EVICTION Trial
12 Nov 2021 //
GLOBENEWSWIRE
ImCheck Publishes Comprehensive Overview of Devp Results of Its First-in-class
20 Oct 2021 //
GLOBENEWSWIRE
ImCheck to Present Updated Patient Response Data from the EVICTION
01 Oct 2021 //
GLOBENEWSWIRE
ImCheck Presents Data from the Phase I/IIa EVICTION Trial with ICT01
17 Sep 2021 //
GLOBENEWSWIRE
ImCheck Publishes Seminal Paper in Cell Reports
13 Jul 2021 //
GLOBENEWSWIRE
ImCheck Announces Initiation of U.S. Enrollment in PhI/IIa EVICTION for ICT01
26 Apr 2021 //
GLOBENEWSWIRE
ImCheck to Present Data Demonstrating Activation of the Anti-Tumor
11 Mar 2021 //
GLOBENEWSWIRE
ImCheck Presents at SITC First Clinical of Gamma Delta T Cell Activation
11 Nov 2020 //
PIPELINEREVIEW
ImCheck Announces Four ICT01 Abstracts Accepted for Presentation at the Society
14 Oct 2020 //
GLOBENEWSWIRE
ImCheck adds $7.1M, boosting development of gamma delta T cell programs
15 Sep 2020 //
ENDPOINTS
ImCheck Achieves Positive Independent Safety Review and Initiates Next Stage
10 Sep 2020 //
GLOBENEWSWIRE
Pfizer Ventures helps gamma delta player ImCheck to $53M round
04 Dec 2019 //
FIERCE PHARMA
